It didn’t capture banner headlines, but a news story that broke in mid-November suggests why private equity investors may finally be paying attention to companies working with human stems cells.
Office of Strategic Communication
It didn’t capture banner headlines, but a news story that broke in mid-November suggests why private equity investors may finally be paying attention to companies working with human stems cells.